Trials / Unknown
UnknownNCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
A Single-center, Randomized, Active-controlled, Parallel-group, Double-blind, Phase I Clinical Trial to Evaluate Safety and Immunogenicity of Hexavalent Vaccine (APV006) in Healthy Adults
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DTaP-HepB-IPV-Hib vaccine | Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine) |
| BIOLOGICAL | DTaP-HepB-IPV-Hib vaccine | Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine) |
Timeline
- Start date
- 2023-07-17
- Primary completion
- 2023-10-31
- Completion
- 2024-03-31
- First posted
- 2023-07-19
- Last updated
- 2023-07-19
Source: ClinicalTrials.gov record NCT05952596. Inclusion in this directory is not an endorsement.